Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo

Expert Opinion on Drug Delivery

Volumn 7, Issue 12, 2010, Pages 1329-1341

  Dicko, Awa ^a   Mayer, Lawrence D ^a   Tardi, Paul G ^a  

^a Celator Pharmaceuticals Corp   (Canada)

Author keywords

combination chemotherapy; drug delivery; liposome; nanoparticle; synergy

Indexed keywords

BUFFER; CHOLESTEROL; CISPLATIN; CYTARABINE; DAUNORUBICIN; FLOXURIDINE; GLUCONATE COPPER; IRINOTECAN; LIPOSOME; NANOPARTICLE; PHOSPHATIDIC ACID; PHOSPHATIDYLSERINE; PLASMA PROTEIN; TRIETHANOLAMINE;

BINDING AFFINITY; CANCER THERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; DRUG RETENTION; ENCAPSULATION; HUMAN; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; HYDROPHOBICITY; IN VIVO STUDY; LIPID MEMBRANE; LIPOSOMAL DELIVERY; LUNG SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MEMBRANE PERMEABILITY; METASTASIS; MYELOID LEUKEMIA; NANOANALYSIS; NANOENCAPSULATION; NANOTECHNOLOGY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; HUMANS; LIPOSOMES; NANOPARTICLES; NEOPLASMS;

EID: 78649947932     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2010.538678     Document Type: Review

References (74)

1. Freireich EJ, Frei E III. Recent advances in acute leukemia. Prog Hematol 1964;27:187-202
2. Frei E III, Freireich EJ. Leukemia. Sci Am 1964;210:88-96
3. Abraham SA, McKenzie C, Masin D, et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 2004;10:728-38
4. Harasym TO, Tardi PG, Johnstone SA, et al. Fixed drug ratio liposome formulations of combination cancer therapeutics. In: Gregoriadis G, editor, Liposome technology. Interactions of liposomes with biological milieu. 3rd edition. Volume III. Informa Healthcare, Inc., New York, USA; 2007b. p. 25-46
5. Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006;5:1854-63
6. Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 2007;7:216-23
7. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout DC, editors, Synergism and antagonism in chemotherapy. Academic Press, New York; 1991. p. 61-102
8. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55
9. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergsim and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81
10. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331-85
11. Papahadjopoulos D, Cowden M, Kimelberg H. Role of cholesterol in membranes. Effects on phospholipid-protein interactions, membrane permeability and enzymatic activity. Biochim Biophys Acta 1973;330:8-26
12. Semple SC, Chonn A, Cullis PR. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry 1996;35:2521-5
13. Bittman R, Blau L. The phospholipid-cholesterol interaction. Kinetics of water permeability in liposomes. Biochemistry 1972;11:4831-9
14. Papahadjopoulos D, Jacobson K, Nir S, Isac T. Phase transitions in phospholipids vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim Biophys Acta 1973;11:330-48
15. Demel RA, De Kruyff B. The function of sterols in membranes. Biochim Biophys Acta 1976;457:109-32
16. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 1980;186:591-8
17. Senior J, Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation: The effect of the phospholipid and cholesterol components. Life Sci 1982;30:2123-36
18. Ogihara-Umeda I, Kojima S. Cholesterol enhances the delivery of liposome-encapsulated gallium-67 to tumors. Eur J Nucl Med 1989;15:612-17
19. Tardi PG, Gallagher RC, Johnstone SA, et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 2007;1768:678-87
20. Dos Santos N, Mayer LD, Abraham SA, et al. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 2002;1561:188-201
21. Dos Santos N, Waterhouse D, Masin D, et al. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release 2005;105:89-105
22. Parr MJ, Ansell SM, Choi LS, et al. Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim Biophys Acta 1994;1195:21-30
23. Ishida T, Atobe K, Wang X, et al. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection. J Control Release 2006;115:251-8
24. Ishida T, Ichihara M, Wang X, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 2006;112:15-25
25. Laverman P, Brouwers AH, Dams ET, et al. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther 2000;293:996-1001
26. Webb MS, Harasym TO, Masin D, et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995;72:896-904
27. Webb MS, Saxon D, Wong FM, et al. Comparison of different hydrophobic anchors conjugated to poly(ethyleneglycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1998;1372:272-82
28. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988;85:6949-53
29. Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992;267:18759-65
30. Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1992;1103:94-100
31. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987;3:123-93
32. Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743
33. Lancet J, Feldman E, Cortes J, et al. Phase 2b randomized study of CPX-351 vs. conventional cytarabine + daunorubicin in newly diagnosed AML patients aged 60-75: safety report. Blood 2009;114:2033
34. Tardi PG, Johnstone SA, Harasym NL, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009a;33:129-39
35. Mayer LD, Bally MB, Hope MJ, et al. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 1985;813:294-302
36. Cullis PR, Hope MJ, Bally MB, et al. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1997;1331:187-211
37. Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1993;1152:253-8
38. Haran G, Cohen R, Bar LK, et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993;1151(2):201-15
39. Cheung BCL, Sun THT, Leenhouts JM, et al. Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. Biochim Biophys Acta 1998;1414:204-16
40. Grit M, Crommelin DJ. Chemical stability of liposoms: implications for their physical stability. Chem Phys Lipids 1993;64(1-3):3-18
41. Barenholz Y, Amselem S, Goren D, et al. Stability of liposomal doxorubicin formulations: problems and prospects. Med Res Rev 1993;13(4):449-91
42. Foye WO. Role of metal-binding in the biological activities of drugs. J Pharm Sci 1961;50:93-108
43. Drechsel H, Fiallo M, Garnier-Suillerot A, et al. Spectroscopic studies on iron complexes of different anthracyclines in aprotic solvent systems. Inorg Chem 2001;40:5324-33
44. Fiallo MM, Garnier-Suillerot A. Metal anthracycline complexes as a new class of anthracycline derivatives. Pd(II)-adriamycin and Pd(II)- daunorubicin complexes: physicochemical characteristics and antitumor activity. Biochemistry 1986;25:924-30
45. Fiallo M, Laigle A, Garnier-Suillerot A, et al. Interactions of iron-anthracycline complexes with living cells: a microspectrofluorometric study. Biochim Biophys Acta 1993;1177:236-44
46. Fiallo MM, Drechsel H, Garnier-Suillerot A, et al. Solution structure of iron(III)-anthracycline complexes. J Med Chem 1999;42:2844-51
47. Malisza KL, Hasinoff BB. Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch Biochem Biophys 1995;321:51-60
48. Dicko A, Kwak S, Frazier A, et al. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int J Pharm 2010;391:248-59
49. Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001;12:493-96
50. White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006;95:822-8
51. Seetharamu N, Kim E, Hochster H, et al. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res 2010;30:541-5
52. Tardi PG, Dos Santos N, Harasym TO, et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther 2009b;8:2266-75
53. Harasym TO, Tardi PG, Harasym NL, et al. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol Res 2007a;16:361-74
54. Mayer LD, Lim WS, Dos Santos N, et al. Synergistic cytarabine: daunorubicin ratios delivered by CPX-351 to human leukemia xenografts is associated with liposome-mediated bone marrow drug accumulation, intracellular delivery of encapsulated agents to leukemia cells, and increased efficacy. Blood 2008;112:942
55. Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res 2010;34(9):1214-23
56. Bayne WF, Mayer LD, Swenson C. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J Pharm Sci 2009;98:2540-8
57. Takada M, Fukuoka M, Kudoh S, et al. Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice. Proc Am Assoc Cancer Res 1992;33:226
58. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604-10
59. Tsunoda T, Tanimura H, Hotta T, et al. In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer. 2000;73:6-11
60. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91
61. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/ cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-43
62. Natale R. SO124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients with previously untreated extensive stage small cell lung cancer (E-SCLC) [abstract 7512]. ASCO Meeting; 2008
63. Adams DJ, Sandvold ML, Myhren F, et al. Anti proliferative activity of ELACYTTM (CP-4055) in combination with cloretazine (VNP40101M) idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 2008;49:786-97
64. Fahr A, van Hoogevest P, May S, et al. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci 2005;26:251-65
65. Guo W, Johnson JL, Khan S, et al. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. Anal Biochem 2005;336:213-20
66. Skwarczynski M, Hayashi Y, Kiso Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J Med Chem 2006;49:7253-69
67. Hu X, Jing X. Biodegradable amphiphilic polymer-drug conjugate micelles. Expert Opin Drug Deliv 2009;6:1079-90
68. Kratz F, Abu Ajaj K, Warnecke A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin Investig Drugs 2007;16:1037-58
69. Fleming AB, Haverstick K, Saltzman WM. In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain. Bioconjug Chem 2004;15:1364-75
70. Gopin A, Ebner S, Attali B, et al. Enzymatic activation of second-generation dendritic prodrugs: conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry. Bioconjug Chem 2006;17:1432-40
71. Yu D, Peng P, Dharap SS, et al. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo. J Control Release 2005;110:90-102
72. Tong R, Yala L, Fan TM, et al. The formulation of aptamer-coated paclitaxelpolylactide nanoconjugates and their targeting to cancer cells. Biomaterials 2010;31:3043-53
73. Ansell SM, Johnstone SA, Tardi PG, et al. Development of highly efficacious hydrophobic paclitaxel prodrugs delivered in nanoparticles for fixed-ratio drug combination applications [abstracts 5734]. AACR Meeting; 2008a
74. Ansell SM, Johnstone SA, Tardi PG, et al. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. J Med Chem 2008b;51:3288-96